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Abstract
The first examination of a terminal α-fluorovinyl trigger in an amino acid decarboxylase active site
is reported. To investigate the enantiospecifity of inactivation with this new AADC trigger, an
enantioselective synthesis of L-α-(2′Z-fluoro)vinyllysine and its D-antipode has been developed.
Control of stereochemistry is achieved through introduction of the amino acid side chain via
alkylation of a chiral vinylglycine-derived dienolate. Facial selectivity is conferred by a trans-2′(β-
naphthyl)-2′-propylcyclohexyl ester auxiliary, available in both antipodal forms (Comins protocol).
The alkylation employs a new electrophile, N-p-methoxybenzyl-N-(2′-
trimethylsilylethanesulfonyl)-4-iodobutylamine, for convergent installation of the lysine side chain.
Vinyl to 2′-fluorovinyl interconversion then provides L- and D-α-(2′Z-fluoro)vinyllysine in 97–99%
ee, as demonstrated by chiral HPLC. Both time-dependent enzyme kinetics and 19F NMR reveal
striking differences in the behavior of these two antipodes in the lysine decarboxylase active site.
The L-antipode displays time dependent inactivation (t1/2 = 3 ± 1 min.; KI = 86 ± 22 μM) whereas
the D-antipode behaves as a substrate, being completely turned over to α-(2′Z-fluoro)
vinylcadaverine. Titration of LDC with varying amounts of L-α-(2′Z-fluoro)vinyllysine provides an
estimate of 20 ± 3 for the partition ratio for this antipode. 19F NMR provides a more detailed account
of the inactivation with the L-antipode, revealing that 1 in 3.2 turnovers of this mechanism-based
inhibitor result in errant protonation (required by design), with 1 in 5 errant protonation events leading
to LDC inactivation. This gives an overall partition ratio of 16 ± 2. Fluoride-selective electrode
measurements are in agreement with 19F NMR estimates of [fluoride] released.
Mechanism-based enzyme inactivators (MBEI’s)1,2 are useful bioorganic tools to study
enzyme mechanism and to modulate metabolic flux. Moreover, of the over 300 enzyme-
targeted drugs in the FDA Orange Book, most may be considered broadly “mechanism-
based.”3 As such, some combinatorial libraries are now built around MBEI trigger motifs.4
Recently, “suicide triggers” have also found application in screens for catalytic antibodies5
and in activity-based proteomics.6
We describe here the first successful halovinyl trigger for amino acid decarboxylase (AADC)
inactivation, of which we are aware. Among MBEI’s for AADC’s, DFMO (α-
difluoromethylornithine), used clinically for parasitic diseases and as a potential
chemopreventive agent,7 probably is the benchmark. The mechanism of action of the α-
difluoromethyl trigger in the ornithine decarboxylase (ODC) active site has now been
elucidated by a combination of MS8 and X-ray methods,9 and the non-enantioselective nature
of its inactivation has been established.10
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We set out to develop an α-(2′-fluoro)vinyl (2′FV) trigger for AADC inactivation with
projected mechanism(s) as outlined in Scheme 1. The design envisions the normal
transaldimination (to I), and α-decarboxylation (gives II) steps, followed by an errant
protonation at either C4′ of the cofactor (to IV) or at Cγ of the “suicide substrate.” The former
pathway finds precedence in the now crystallographically established11 Michael addition
mechanism12 of the antiepileptic drug, Vigabatrin, though for this target, GABA transaminase,
C4, is the normal locus of protonation. The latter Cγ pathway can branch into a nucleophilic
Metzler enamine pathway,11 and/or into a second electrophilic pathway, initiated by γ-fluoride
expulsion out of intermediate VIII,13 rather than Mannich condensation.
Note again that all three putative AADC inactivation pathways require that the enzyme be
directed into a mistaken protonation of quinonoid intermediate II. The literature provides
insight as to how this detour pathway might be promoted. It is known that installation of an
α-methyl group, to generate a quaternary AA, results in increased errant (C4′) protonation in
the cognate AADC (from typically 0.01–0.1% up to 4% frequency for ODC).14 So, the
placement of the (2′FV) trigger at a quaternary α-center is critical to our design, and is to serve
the dual purpose of (i) dictating specificity for AADC’s over enzymes that labilize the α-proton
(e.g. transaminases, racemases, β- and γ-replacement enzymes), and (ii) promoting the requisite
errant protonation.
We chose L-lysine decarboxylase (LDC) as a model enzyme in which to test this new AADC
trigger, as we had access to multi-milligram quantities of the Hafnia alvei LDC.15 Furthermore,
this class of bacterial LDC was reported to be resistant to covalent modification with the α-
difluoromethyl trigger.16
A stereoselective synthesis of each antipode of the targeted inactivator was achieved as outlined
in Scheme 2. The quaternary center is introduced by alkylation of a chiral vinylglycine-derived
dianionic dienolate.17 As illustrated, our working model for such systems involves (i) the use
of α-nitrogen-based amidate chelation to control enolate geometry and (ii) the application of
auxiliaries of the “arylmenthyl” variety to control facial selectivity.
The use of dienolates outfitted with the Comins auxiliary (available in both antipodal forms)
18 here provides a potentially generalizable method to access both enantiomers of sought after
quaternary AA’s. Following side chain installation, conversion of the α-vinyl group to a 2′Z-
fluorovinyl group proceeds smoothly, following to our recently disclosed protocol.19
L-α-(2′Z-Fluoro)vinyllysine displays time dependent inactivation of LDC, whereas its mirror
image displays little to no inactivation. Kitz-Wilson of the the L-2′FVL data, yields kinact =
0.26 ± 0.07 min−1 and KI = 86 ± 22 μM. This is comparable to the kinact values seen for both
antipodes of DFMO and (S)-Vigabatrin. The KI value is higher than that seen for L-DFMO
(~1.3 μM),10 but significantly lower than that seen for (S)-Vigabatrin (~3 mM).20 Inactivation
was functionally irreversible (dialysis). Curvature in ln(Et/E0) vs. t plots was observed,
suggestive of significant partitioning into natural or unnatural turnover pathways. In fact, a
titration of the enzyme with varying I:E ratios provides an estimate of the partition ratio (total
turnovers per inactivation event) of ~20 ± 3 (Fig. 1).
Fluorine serves both a mechanistic and a labeling role in this trigger. 19F NMR monitoring,
21 of the individual FVL-antipodes (Fig. 2) shows the D-enantiomer to be exclusively a
substrate, whereas the L-antipode is a suicide substrate. Inactivation of 15μM LDC produces
168 ± 14 μM α-(2′fluoro)vinylcadaverine (FVC) turnover product (matches authentic sample)
and 70 ± 13 μM fluoride.22 The fluoride value was confirmed with an ion-specific electrode
(78 ± 5 μM).
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Since all errant protonations are projected to release fluoride, one can estimate that 1 in 3.4
decarboxylations leads to errant protonation (29%!), with 1 in 5 errant protonation events
leading to LDC inactivation. This gives an overall partition ratio of 16 ± 2. The high errant
protonation rate (~8 times the maximum value produced by α-methylation) seen in this model
AADC active site is promising, as altered protonation is required for trigger actuation. γ-
Protonation provides the simplest mechanism for release of four excess equivalents of fluoride,
but this does not exclude any of the three pathways put forth for the inactivation step itself.
This must await the results of further studies. Given the success in driving errant protonation
with L-FVL and its favorable kinact, it will be of interest to examine this trigger in other AADC
active sites. The remarkable enantio-discrimination observed stands in stark contrast to the
case of DFMO, and underscores the value of interrogating individual antipodes in MBEI
studies.
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Figure 1.
Titration of LDC with L-2′FVL (two trials, color-coded)
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Figure 2.
19F NMR spectral acquisitions monitoring the reaction course taken by the L- (top) and D-
enantiomer (bottom) of α-(2′Z-fluoro)vinyllysine ([I]:[E] = 75:1), upon incubation with Hafnia
alvei LDC (15 μM) at pH 6.0, for the indicated times. Parallel kinetic assays show 92%
inactivation for the L-antipode in 10 min, and complete knockout in <1 h, accounting for the
invariant NMR spectrum for L-FVL (essentially unchanged @ t =16 h, see SI).
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Scheme 1.
Projected Mechanisms for the 2′FV-AADC Trigger
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Scheme 2.
Stereoselective Introduction of the 2′FV-AADC Trigger
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